|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM120758938 |
| 003 |
DE-627 |
| 005 |
20231222191554.0 |
| 007 |
tu |
| 008 |
231222s2002 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0403.xml
|
| 035 |
|
|
|a (DE-627)NLM120758938
|
| 035 |
|
|
|a (NLM)12217332
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Quinti, Isabella
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a European surveillance of immunoglobulin safety--results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries
|
| 264 |
|
1 |
|c 2002
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.11.2002
|
| 500 |
|
|
|a Date Revised 06.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a CommentIn: Clin Immunol. 2002 Sep;104(3):201-3. - PMID 12217328
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A European multicenter study was conducted to obtain information on the current practices of immunoglobulin administration, the policies in use for the surveillance of the risk of hepatitis C virus (HCV) transmission, and the natural history of HCV infection in patients with hypogammaglobulinemia. Data from 1243 patients with primary immunodeficiencies in 16 countries demonstrated that 90% of patients with antibody deficiencies receive intravenous immunoglobulins in an inpatient setting, and 7% of patients are treated with subcutaneous immunoglobulins, mainly at home. Wide variations have been reported regarding the frequency and the type of tests monitored for the surveillance on the risk of viral hepatitis transmission. Only 60% of patients have been tested at least once for HCV RNA detection. Data from 71 HCV-infected patients demonstrated a rapid progression of HCV infection, with end-stage liver disease, in about 40% of patients. Ten percent of patients spontaneously cleared the virus, and about 30% are asymptomatic. Patients with CVID have a worse prognosis than patients with XLA
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Immunoglobulins
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 650 |
|
7 |
|a RNA, Viral
|2 NLM
|
| 700 |
1 |
|
|a Pierdominici, Marina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Marziali, Marco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Giovannetti, Antonello
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Donnanno, Simona
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chapel, Helen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bjorkander, Janne
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aiuti, Fernando
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a European Study Group for the Surveillance of Immunoglobulin Safety
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 104(2002), 3 vom: 01. Sept., Seite 231-6
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:104
|g year:2002
|g number:3
|g day:01
|g month:09
|g pages:231-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 104
|j 2002
|e 3
|b 01
|c 09
|h 231-6
|